How Long Does It Take to Recover from Henoch-Schönlein Purpura Nephritis?

IgA nephropathy, also known as Berger’s disease, is a chronic autoimmune kidney disorder characterized by the deposition of immunoglobulin A (IgA) immune complexes in the glomerular mesangium. The clinical course varies significantly among individuals—some patients experience stable, asymptomatic hematuria and mild proteinuria for decades, while others progress to progressive glomerulosclerosis and, ultimately, end-stage kidney disease.

There is no universally defined “recovery” timeline for IgA nephropathy because it is generally considered a lifelong condition requiring ongoing monitoring and management. Unlike acute kidney injuries that may resolve completely with time and treatment, IgA nephropathy involves persistent immune dysregulation and structural changes in the glomeruli. While certain patients—particularly children and young adults with isolated microscopic hematuria and minimal proteinuria—may maintain stable kidney function for many years without intervention, true histologic or immunologic “cure” remains rare.

Clinical remission—defined as sustained absence of active urinary abnormalities (e.g., normalization of urine red blood cells and reduction of proteinuria to <0.5 g/day) and stable estimated glomerular filtration rate (eGFR) over at least 6–12 months—is achievable in a subset of patients, especially with early, guideline-concordant therapy. Such therapy may include optimized supportive care (e.g., ACE inhibitors or ARBs for blood pressure and proteinuria control), sodium restriction, smoking cessation, and, in high-risk cases, immunosuppressive regimens such as corticosteroids or newer agents like budesonide (targeted release to the gut-associated lymphoid tissue) or rituximab in select refractory presentations.

Prognosis depends on multiple factors: baseline eGFR, degree of proteinuria (>1 g/day confers higher risk), presence of hypertension, extent of interstitial fibrosis or tubular atrophy on biopsy, and histopathologic features per the Oxford MEST-C classification (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, and crescents). Patients with favorable profiles may remain stable for 10–20 years or longer; those with aggressive disease may lose significant kidney function within 5–10 years without effective intervention.

Long-term follow-up is essential. Regular assessment of serum creatinine, eGFR, urine albumin-to-creatinine ratio (UACR), and blood pressure enables timely detection of progression and adjustment of therapy. Emerging biomarkers—including galactose-deficient IgA1 levels and anti-glycan antibodies—are under investigation to refine risk stratification and personalize treatment duration and intensity.